On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.
Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.
Generative AI protein engineering specialist Cradle NV, has raised US$24m in a Series A financing round led by Index Ventures w
British and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain.
French Sanofi SAs second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.
In the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe.
Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.